PARK2 Polyclonal Antibody

Rabbit Anti-PARK2 Polyclonal Antibody

Product Specifications

Background

The precise function of PARK2 is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in PARK2 are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support.

CAS Number

9007-83-4

Product Name Alternative

PARK2; PRKN; E3 ubiquitin-protein ligase parkin; Parkinson juvenile disease protein 2; Parkinson disease protein 2

Gene ID

5071

Accession Number

O60260

Reactivity

Human, Mouse, Rat

Immunogen

Synthesized peptide derived from the N-terminal region of human PARK2 at AA range: 1-80

Clonality

Polyclonal

Tag

E3 ubiquitin-protein ligase parkin

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

52kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

PARK2 Polyclonal Antibody detects endogenous levels of PARK2 protein.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:20000; Not yet tested in other applications.